Researchers from Finland and Estonia have discovered novel biological markers that are strongly indicative of risk of dying from any disease within the near future.
Blood samples from over 17 000 generally healthy people were screened for more than a hundred different biomolecules. The health status of these study volunteers was followed for several years, and the researchers looked for measures in the blood that could reflect who had died within the following 5 years after the blood sample was taken.
In a study published in PLOS Medicine they describe identification of four such biomarkers of death.
The identified biomarkers were albumin, alpha-1-acid glycoprotein, citrate and the size of very-low-density lipoprotein particles. Of these, albumin was the only one previously linked with mortality. All these molecules are normally present in everyone’s blood, but it is the amount of these molecules that was shown to be important.
The novel biomarkers helped to detect individuals at much higher risk of dying during the five-year follow-up. The measures were independent of well-known risk factors such as age, smoking, drinking, obesity, blood pressure and cholesterol. The result did not change even when only apparently healthy persons were examined.
– What is especially interesting is that these biomarkers reflect the risk for dying from very different types of diseases such as heart disease or cancer. They seem to be signs of a general frailty in the body. Next we aim to study whether some kind of connecting factor between these biomarkers can be identified, says Dr. Johannes Kettunen from the University of Helsinki.
– We believe that in the future these measures can be used to identify people who appear healthy but in fact have serious underlying illnesses and guide them to proper treatment. More studies are, however, needed before these findings can be implemented in clinical practice.
The discovery of these new biomarkers was possible thanks to a technology called NMR spectroscopy. This method, developed in Finland, allows screening of large amounts of blood samples in a cost-effective manner.
The research was conducted in collaboration between the Institute for Molecular Medicine Finland FIMM, University of Helsinki, and Finnish National Institute for Health and Welfare, University of Oulu, University of Eastern Finland, and the Estonian Biobank.